In patients with very advanced (unresectable/ inoperable/recurrent or metastatic) disease, a multidisciplinary approach must be considered when evaluating recurrent or distantly metastasized disease to decide next course of treatment (surgery or re-irradiation, with or without chemotherapy). For patients with newly diagnosed but unresectable disease, the treatment goal is the cure. While for the recurrent disease group, the goal is either cure (if surgery or radiation remains feasible) or palliation (if the patient has received previous radiotherapy [RT] and the disease is unresectable). For patients with metastatic disease, the goal is palliation or prolongation of life.
Newly diagnosed (M0) T4b, N0-3/Unresectable nodal disease/Unfit for surgery Chemotherapy and radiotherapy (CT/RT)
For patients who are unsuitable for surgery or with unresectable disease due to anatomical difficulty, chemoradiotherapy (CTRT) (evidence level [EL] 2; Grade C) [1] or RT with cetuximab should be considered than RT alone. High-dose cisplatin with RT is effective.
CT regimens for cisplatin suitable patients include (a) three-weekly cisplatin 100 mg, (b) nimotuzumab + weekly 30 or 40 mg/m 2 cisplatin, (c) weekly cisplatin 30 or 40 mg/m 2 , (d) cisplatin + paclitaxel, or (e) cisplatin + infusional 5-fluorouracil (FU). However, CT regimens for cisplatin unsuitable patients include (a) weekly cetuximab, (b) weekly nimotuzumab, (c) carboplatin + infusional 5-FU, (d) 5-FU + hydroxyurea, or (e) carboplatin + paclitaxel.
For high-risk patients, typically 70 Gy (2.0 Gy/fraction) and for low-to-intermediate risk patients, 44-50 Gy (2.0 Gy/fraction) to 54-63 Gy (1.6-1.8 Gy/fraction) of radiation are recommended. Volume 57 | Supplement 1 | 2020
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Very Advanced Disease of Head and neck cancer management: Indian consensus guidelines tumor cells with membranous PD-L1 staining) ≥50%. Pembrolizumab is recommended as a single agent in patients with a combined positive score (CPS) ≥20, and in combination with or without platinum plus FU in patients with CPS ≥1 and <20 (EL 1; Grade A) [5, 6] (c) Nivolumab is recommended as single agent if disease has progressed during or within 6 months of platinum-based therapy (EL 1; Grade A) [7] (d) Cisplatin/5-FU (e) Cisplatin or carboplatin/docetaxel or paclitaxel (f) Cisplatin or carboplatin/docetaxel/cetuximab (g) Cisplatin or carboplatin/paclitaxel/cetuximab.
Single-agent systemic therapy with cisplatin, carboplatin, paclitaxel, docetaxel, 5-FU, methotrexate, cetuximab, gemcitabine, or capecitabine can be considered.
Recurrent or persistent disease
In patients with recurrent or metastatic disease, palliative treatment should be considered. Symptomatic relief, particularly, pain and the management of nutrition, is important in the overall management. Using chemotherapeutic agents (like cisplatin plus 5-FU, carboplatin plus paclitaxel, or carboplatin plus docetaxel) is recommended. Addition of cetuximab can improve overall survival. [4, 8] Patients who progress following initial treatment with systemic platinum-based CT (with or without cetuximab) and eligible for immunotherapy pembrolizumab or nivolumab are the treatment of choice (EL 1; Grade A).
Pembrolizumab is recommended as a single agent in patients with CPS ≥20, and in combination with or without platinum plus FU in patients with CPS ≥1 and <20 (EL 1; Grade A). [5, 6] Nivolumab is recommended as a single agent if disease has progressed during or within 6 months of platinum-based therapy (EL 1; Grade A). [7] Patients who are not eligible for immunotherapy, single agent, or combination therapy of platinum plus taxane are recommended or 5-FU or methotrexate can also be considered.
Treatment of resectable recurrent/persistent disease should be surgery followed by postoperative CTRT or postoperative RT. Choice of adjuvant treatment should be based on the findings of the surgery/ neck dissection. In case of no adverse features, observation should be done. In case of recurrent disease extranodal extension/positive margin, adjuvant CT/RT and in case of other adverse events like pT3 or pT4, primary, N2 or N3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular Induction CT Induction CT followed by RT is also one option. [2, 3] Cisplatin-based induction CT regimens are as follows:
• Docetaxel 75 mg/m 2 on day 1 + cisplatin 75 mg/m 2 on day 1 + 5-FU 750 mg/m 2 /day for 5 days every 3 weeks for three cycles • Paclitaxel 175 mg/m 2 on day 1 + cisplatin 100 mg/m 2 on day 2 + 5-FU 500-750 mg/m 2 /day from day 2 to day 6 every 3 weeks for three cycles • Cisplatin 100 mg/m 2 on day 1 + 5-FU 1000 mg/m 2 /day for 4 days every 3 weeks for three cycles. • 50 Gy in 20 fractions or 37.5 Gy in 15 fractions (if well tolerated, consider adding 5 additional fractions to 50 Gy) or • 30 Gy in 10 fractions or 30 Gy in 5 fractions: Give 2 fractions/week with ≥3 days between the two treatments or 44.4 Gy in 12 fractions, in three cycles (for each cycle, give 2 fractions 6 hours apart, for 2 days in a row, and treatments must exclude spinal cord after second cycle).
Systemic therapy
Single-agent systemic therapy including cisplatin/carboplatin/paclitaxel/docetaxel/5-FU/ methotrexate/cetuximab/gemcitabine/capecitabine combination CT may be considered. Immunotherapy alone or in combination with CT has improved survival and need to be considered. Metronomic CT has also shown to improve progression-free survival and quality of life and also is a valuable option.
Metastatic (M1) disease at initial presentation
Locoregional treatment prior to beginning systemic therapy may be considered. Single agents and combination systemic therapy regimens are both used.
Combination systemic therapy includes: (a) Cisplatin or car boplatin /5 -FU/cetuximab [4] (EL 1; Grade A) (b) Pembrolizumab monotherapy or pembrolizumab for patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (percentage of embolism, and lymphatic invasion, CT/RT should be considered. [9] [10] [11] Other treatment options for resectable recurrent/persistent disease are concurrent CT/RT or induction CT followed by CT or CT/RT.
Adjuvant CTRT schedules include:
• CT: 100 mg/m 2 three weekly cisplatin/30 or 40 mg/m 2 weekly cisplatin or 5-FU and hydroxyurea [12] [13] [14] Algorithm for management of very advanced disease is given in Figure 1 . Appendix 3 and 4 give the summary of clinical evidences in locally advanced and recurrent and/or metastatic disease.
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